The used mathematical model does not account for the heterogeneity of receptor expression within the cancer cell population, and we are unaware of literature data quantitatively addressing the heterogeneity of CD38 expression in multiple myeloma lesions. The gene discussed is CD38; the disease is AL amyloidosis.